Abstract: 0.03% Tacrolimus
To report the clinical outcome of the treatment of dry eyes using 0.03% tacrolimus eye drops.
Sixteen eyes of 8 patients with Sjögren syndrome dry eyes (age, 51.13 ± 9.45 years) were enrolled in this study (prospective noncontrolled interventional case series). Patients were instructed to use topical 0.03% tacrolimus eye drops twice a day (every 12 hours) in the lower conjunctival sac. Schirmer I test, break-up time, corneal fluorescein, and rose bengal staining score were performed in all patients 1 day before, and 14, 28, and 90 days after treatment with 0.03% tacrolimus eye drops.
The average fluorescein staining and rose bengal staining scores improved statistically significantly after 14 days of treatment and improved even more after 28 and 90 days. The average Schirmer I test did not improve statistically significantly after 28 days of treatment, although we did observe a significant improvement after 90 days of treatment with 0.03% tacrolimus eye drops. The average break-up time did not improve statistically after 14 days of treatment, although we observed a significant improvement after 28 and 90 days of treatment with 0.03% tacrolimus eye drops.
Topical 0.03% tacrolimus eye drops successfully improved tear stability and ocular surface status in patients with dry eyes.
Cornea. 2012 Apr 16. [Epub ahead of print]
*Department of Ophthalmology, School of Medicine, University of São Paulo (Hospital das Clínicas of da Universidade de São Paulo), São Paulo, Brazil †Department of Ophthalmology, Santa Casa de São Paulo, São Paulo, Brazil ‡Department of Ophthalmology, Tokyo Dental College, Chiba, Japan.